Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2019 to Aug 2024
![Click Here for more Affymetrix Charts. Click Here for more Affymetrix Charts.](/p.php?pid=staticchart&s=N%5EAFFX&p=8&t=15)
Affymetrix Achieves ISO Certification for Instrumentation and
Microarray Manufacturing Facilities
-- Certification Marks Critical Milestone on Path to Diagnostic Products in
European Marketplace --
SANTA CLARA, Calif., Aug. 31 /PRNewswire-FirstCall/ -- Affymetrix, Inc.,
(NASDAQ:AFFX) today announced that both its instrument and microarray
manufacturing facilities, located in Bedford, MA and West Sacramento, CA,
respectively, have been audited by TUV America and have received ISO
certification. The achievement of ISO certification confirms that quality
systems have been implemented in product development, operations, shipping, and
service and will support CE marking of future Affymetrix products that will be
labeled for in-vitro diagnostic use for sale within the European Community.
"Affymetrix takes pride in its commitment to delivering the highest-quality
microarray products manufactured for the life sciences business," said Rob
Lipshutz, Senior Vice President of Molecular Diagnostics and Emerging Markets
at Affymetrix. "This certification recognizes our ability to deliver high
quality products to the diagnostics market and represents an important
component required for regulated diagnostic products."
Affymetrix technology has been used in nearly 3,000 scientific publications to
discover the basic underpinnings of diseases such as cancer, multiple
sclerosis, and numerous developmental disorders. ISO certification represents
an important step in developing new array-based diagnostic tools that will more
directly impact the patient, enabling physicians to stratify disease, predict
outcome, and make therapeutic choices in ways never before possible.
A growing community of businesses have partnered with Affymetrix to develop
diagnostic microarray products for both clinical and non-clinical markets.
Instrumentation and microarrays manufactured in Affymetrix' ISO compliant
facilities will be made available to these "Powered by Affymetrix" partners in
order to accelerate the design and launch of future diagnostic systems in the
European Union. Under terms of the "Powered by Affymetrix" program, Affymetrix
manufactures the microarrays and instruments, while the diagnostic partner
develops and commercializes the test. The resulting microarray products enable
users to examine genomic sequences in more detail than ever before, providing a
more efficient and complete method to diagnose a wide range of conditions and
create potential solutions.
About Affymetrix:
Affymetrix is a pioneer in creating breakthrough tools that are driving the
genomic revolution. By applying the principles of semiconductor technology to
the life sciences, Affymetrix develops and commercializes systems that enable
scientists to improve quality of life. The Company's customers include
pharmaceutical, biotechnology, agrichemical, diagnostics and consumer products
companies as well as academic, government and other non-profit research
institutes. Affymetrix offers an expanding portfolio of integrated products
and services, including its integrated GeneChip(R) brand platform, to address
growing markets focused on understanding the relationship between genes and
human health. Additional information on Affymetrix can be found at
http://www.affymetrix.com/ .
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies" or the like.
Such statements are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected, including,
but not limited to risks of the Company's ability to achieve and sustain higher
levels of revenue, higher gross margins, reduced operating expenses,
uncertainties relating to technological approaches, manufacturing, product
development (including uncertainties relating to the development of diagnostic
products), market acceptance, personnel retention, uncertainties related to
cost and pricing of Affymetrix products, dependence on collaborative partners,
uncertainties relating to sole source suppliers, uncertainties relating to FDA
and other regulatory approvals, competition, risks relating to intellectual
property of others and the uncertainties of patent protection and litigation.
These and other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2003 and other SEC reports, including its Quarterly
Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to reflect any
change in Affymetrix' expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks
owned or used by Affymetrix, Inc.
DATASOURCE: Affymetrix, Inc.
CONTACT: Media Contact: Wes Conard, Assoc. Director, Public Relations,
+1-408-731-5791, or +1-415-385-4455; or Investor Contact: Doug Farrell, Vice
President, Investor Relations, +1-408-731-5285
Web site: http://www.affymetrix.com/